Control BionicsASX:CBL +4.29% 14-Day RSI is 45.53 as of Jul. 11, 2026. The stock has 4 warning signs investors should review. Among 868 Medical Devices & Instruments companies, Control Bionics ranks better than 72.12% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-11), Control Bionics's 14-Day RSI is 45.53.
The industry rank for Control Bionics's 14-Day RSI or its related term are showing as below:
ASX:CBL's 14-Day RSI is ranked better than 72.12% of 868
companies
in the Medical Devices & Instruments industry
Industry Median: 47.05
vs ASX:CBL: 45.53
Control Bionics (ASX:CBL) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Control Bionics 14-Day RSI Related Terms
ASX:CBL vs ABT, SYK, MDT: 14-Day RSI Comparison
For the Medical Devices subindustry, Control Bionics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Control Bionics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Control Bionics (ASX:CBL) has a 14-Day RSI of 45.53 as of Jul. 11, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Control Bionics and its competitors. According to the industry distribution chart, Control Bionics ranks #242 out of 868 companies in the Medical Devices & Instruments industry, placing it in the top 27.9%.
Is Control Bionics' 14-Day RSI too high?
Control Bionics' current 14-Day RSI is 45.53. The Medical Devices & Instruments industry median 14-Day RSI is 47.05. Control Bionics' value of 45.53 is 3.2% below this industry median. Based on the distribution chart, Control Bionics ranks #242 out of 868 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Control Bionics' 14-Day RSI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #242 out of 868 companies for 14-Day RSI. This puts Control Bionics in the upper half of its industry. The industry median 14-Day RSI is 47.05. Control Bionics' value of 45.53 is 3.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 47.05, based on 868 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Control Bionics's current 14-Day RSI of 45.53 is 3.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 47.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current 14-Day RSI is 45.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.07 — trading 143.3% above its estimated fair value. The current 14-Day RSI is 45.53 and 3.2% below the Medical Devices & Instruments industry median of 47.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current 14-Day RSI is 45.53 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your